Precipio, Inc.
PRPO
Positions held
Your positionsPRPO isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $41.51M | Enterprise value | $42.03M | Trailing P/E | — | Forward P/E | 59.46 |
| PEG | — | Price / book | 2.81 | Beta | 1.30 | Dividend yield | 0.00% |
| Revenue growth | 24.2% | Earnings growth | — | Gross margin | 44.1% | Operating margin | -8.5% |
| Profit margin | -4.5% | ROE | -9.0% | ROA | -4.8% | Debt / equity | 0.24 |
| Current ratio | 1.77 | Free cash flow | $1.35M | Analyst recommendation | none | Mean target | — |
| 52w high | $33.63 | 52w low | $16.40 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $7.0M | $6.7M | $6.7M | $6.8M | $5.7M | — |
| Op margin | -8.5% | -21.3% | 8.1% | -0.9% | -14.6% | — |
| Net income | -$0.2M | -$1.4M | $0.5M | -$0.1M | $0.1M | — |
| Gross margin | 44.7% | 40.6% | 46.8% | 44.4% | 43.0% | — |
| Gross profit | $3.1M | $2.7M | $3.1M | $3.0M | $2.4M | — |
| Operating income | -$0.6M | -$1.4M | $0.5M | -$0.1M | -$0.8M | — |
- Revenue +5% vs prior quarter ($7.0M vs $6.7M).
- Gross margin 44.7% (was 40.6% prior quarter).
- Operating margin expanded to -8.5%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $24.0M | $18.5M | $15.2M | $9.4M | — |
| Op margin | -5.0% | -22.7% | -50.1% | -136.0% | — |
| Net income | -$0.4M | -$4.3M | -$5.9M | -$12.2M | — |
| Gross margin | 44.5% | 40.8% | 39.6% | 26.7% | — |
| Gross profit | $10.7M | $7.6M | $6.0M | $2.5M | — |
| Operating income | -$1.2M | -$4.2M | -$7.6M | -$12.8M | — |
Headlines — positive tone
• [OK · fundamentals] Precipio Inc (PRPO) (Q2 2026) Earnings Call Highlights: Record Revenue and Positive EBITDA Mark ...
News
2026-09-22 · PRPO vs. FLGT: Which Cancer Diagnostics Stock Has More Upside Now?
2026-09-11 · The Zacks Analyst Blog Highlights Goldman Sachs, RTX, Abbott, NLI and Precipio
2026-09-10 · Top Research Reports for Goldman Sachs, RTX & Abbott
2026-08-24 · PRPO vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now?
2026-08-21 · Precipio Stock Gains Post Q2 Earnings, Revenue Momentum Strong
2026-08-21 · Precipio Inc (PRPO) (Q2 2026) Earnings Call Highlights: Record Revenue and Positive EBITDA Mark ...
2026-08-15 · Precipio, Inc. Q2 2026 Earnings Call Summary
2026-08-14 · Precipio Announces Q2-2026 Financial Results
2026-07-31 · Precipio Announces Q2-2026 Shareholder Update Call
2026-07-16 · PRPO vs. NEO: Which Cancer Diagnostics Stock Is the Better Buy?
Price (daily)
Full chart · RSI · MACD · patterns